Oral and inactivated poliovirus vaccines in the newborn: A review

Vaccine

Volumn 31, Issue 21, 2013, Pages 2517-2524

  Mateen, Farrah J ^a,b,c   Shinohara, Russell T ^c   Sutter, Roland W ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Birth; Immunogenicity; Inactivated; Newborn; Oral; Polio vaccine; Poliomyelitis; Poliovirus vaccine; Vaccine

Indexed keywords

INACTIVATED VACCINE; ORAL POLIOMYELITIS VACCINE; TRIPLE VACCINE;

ADVERSE OUTCOME; CLINICAL EVALUATION; FLACCID PARALYSIS; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INDIA; LANGUAGE; MEDICAL DOCUMENTATION; MEDLINE; NEWBORN PERIOD; POLIOMYELITIS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; UMBILICAL CORD BLOOD;

HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84877822298     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.06.020     Document Type: Review

References (47)

1. Global polio eradication initiative. Data and monitoring. [last accessed 26.11.11]. http://www.polioeradication.org/.
2. World Health Organization. Europe achieves historical milestone as Region is declared polio polio-free [Media release] [21.06.02].
3. Centers for Disease Control and Prevention (CDC) International notes certification of poliomyelitis eradication-the Americas, 1994. MMWR Morb Mortal Wkly Rep 1994, 43:720-722.
4. World Health Organization Western Pacific Region. Western Pacific Region marks public health victory-polio-free status achieved [Press release]; 2001.
5. Polio Eradication Committee, Indian Academy of Pediatrics Recommendations of 2nd national consultative meeting of Indian Academy Of Pediatrics (IAP) on polio eradication and improvement of routine immunization. Indian Pediatr 2008, 45:367-378.
6. Mohammed A.J., AlAwaidy S., Bawikar S., Kurup P.J., Elamir E., Shaban M.M., et al. Fractional doses of inactivated poliovirus vaccine in Oman. N Engl J Med 2010, 362:2351-2359.
7. Risk assessment: frequency and burden of VAPP, cVDPV and iVDPV. In: Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis, Geneva; 13-14 November 2002.
8. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13:926-939.
9. Grassly N.C., Fraser C., Wenger J., Deshpande J.M., Sutter R.W., Heymann D.L., et al. New strategies for the elimination of polio from India. Science 2006, 314:1150-1153.
10. Cáceres V.M., Sutter R.W. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001, 33:531-541.
11. Grassly N.C., Wenger J., Durrani S., Bahl S., Deshpande J.M., Sutter R.W., et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine. Lancet 2007, 369:1356-1362.
12. Advisory committee on poliomyelitis eradication: recommendations on the use of bivalent oral poliovirus vaccine types 1 and 3. Wkly Epidemiol Rec 2009, 84:289-290.
13. World Health Organization Expanded programme on immunization. Wkly Epidemiol Rec 1985, 60:13-20.
14. De-Xiang D., Xi-Min H., Wan-jun L., Jin-Shen L., Yu-cai J., Shun-ge T., et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bull WHO 1986, 64:853-860.
15. John T.J. Immune response of neonates to oral poliomyelitis vaccine. BMJ 1984, 298:881.
16. Halsey N.A., Galazka A. The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age. Bull WHO 1985, 63:1151-1169.
17. Robertson S. The immunological basis for immunization series. Module 6: Poliomyelitis. World Health Organization, Geneva. WHO/EPI/GEN/93.16.
18. United Nations World economic situation and prospects. [last accessed 26.11.11]. http://www.un.org/en/development/desa/policy/wesp/index.shtml.
19. Cohen-Abbo A., Culley B.S., Reed G.W., Sannella E.C., Mace R.L., Robertson S.E., et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Pediatr Infect Dis J 1995, 14:100-106.
20. Prem K.A., McKelvey J.L., Fergus J. Immunologic response of infants under six months of age to oral trivalent poliomyelitis vaccine. 1st international conference on live polio vaccines (Pan American Health Organization) 1959, 254-258.
21. Krugman S., Warren J., Eiger M.S., Berman P.H., Michaels R.H., Sabin A.B. Immunization of newborn infants with live attenuated poliovirus vaccine. 2nd International Conference on Live Polio Vaccines (Pan American Health Organization) 1960, 315-321.
22. Pagano J.S., Plotkin S.A., Koprowski H. Variations in the responses of infants to living attenuated poliovirus vaccines. N Engl J Med 1961, 264:155-163.
23. Campillo-Sainz C., Hernandez A.O., de Mucha Macías J., Nava S.E. Immunization of newborn children with living oral trivalent poliovirus vaccine. J Bacteriol 1962, 84:446-450.
24. Sabin A.B. Problems in the development and use of oral poliovirus vaccine. Clin Pharmacol Ther 1963, 4:573-579.
25. Sabin A.B., Michaels R.H., Ziring P., Krugman S., Warren J. Effect of oral poliovirus vaccine in newborn children: II. Intestinal resistance and antibody response at 6 months in children fed type I vaccine at birth. Pediatrics 1963, 641-650.
26. Ordónez de la Mora B.R., Campillo Sáinz C. Aplicacion simultanea de las vacunas antituberculosa BCG y antipoliomielitica Sabin a recien nacidos. [Spanish] Boletín de la oficina sanitaria Panamericana 1966, 488-494.
27. Farmer K., Armstrong L.V. The serological response of neonates to oral poliovirus vaccine. N Z Med J 1969, 70:168-170.
28. Banfi A., Vergara M.I., Avendaño O., Borgoño J.M., Greiber R., Solari G., et al. Vacunación del recién nacido con vacuna antipoliomieltíca oral Sabin tipo I-Estudio Serológico. Rev Chil Pediatr 1974, 45:491-493.
29. Swartz T.A., Handsher R., Stoeckel P., Drucker J., Caudrelier P., Van Wezel A.L., et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989, 5:141-145.
30. Weckx L.Y., Schmidt B.J., Herrmann A.A., Miyasaki C.H., Novo N.F. Early immunization of neonates with trivalent oral poliovirus vaccine. Bull WHO 1992, 70:85-91.
31. Khare S., Kumari S., Nagpal I.S., Sharma D., Verghese T. Oral polio vaccination in infants: beneficial effect of additional dose at birth. Indian J Pediatr 1993, 60:275-281.
32. Sutter R.W., Patriarca P.A., Suleiman A.J., Pallansch M.A., Zell E.R., Malankar P.G., et al. Paralytic poliomyelitis in Oman: association between regional differences in attack rate and variations in antibody responses to oral poliovirus vaccine. Int J Epidemiol 1993, 22:936-944.
33. Osei-Kwasi M., Afari E.A., Mimura K., Obeng-Ansah I., Ampofo W.K., Nkrumah F.K. Randomized, controlled trial of trivalent oral poliovirus vaccine (Sabin) starting at birth in Ghana. Bull WHO 1995, 73:41-46.
34. Linder N., Yaron M., Handsher R., Kurint J., Birenbaum E., Mazkereth R., et al. Early immunization with inactivated poliovirus vaccine in premature infants. J Pediatr 1995, 127:128-130.
35. Bhaskaram P., Madhavan Nair K., Hemalatha P., Murthy N., Nair P. Systemic and mucosal immune response to polio vaccination with additional dose in newborn period. J Trop Pediatr 1997, 43:232-234.
36. Jain P.K., Dutta A.K., Nangia S., Khare S., Saili A. Seroconversion following killed polio vaccine in neonates. Indian J Pediatr 1997, 64:511-515.
37. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995, 171:1097-1106.
38. Linder N., Handsher R., German B., Sirota L., Bachman M., Zinger S., et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed 2000, 83:F24-F27.
39. Parent du Châtelet I., Merchant A.T., Fisher-Hoch S., Luby S.P., Plotkin S.A., Moatter T., et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 1710-1718.
40. El-Sayed N., El-Gamal Y., Abbassy A., Seoud I., Salama M., Kandeel A., et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008, 359:1655-1665.
41. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial. Lancet 2010, 376:1682-1688.
42. Waggie Z., Geldenhuys H., Sutter R.W., Jacks M., Mulenga H., Mahomed H., et al. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa. J Infect Dis 2012, 205:228-236.
43. Conclusions and recommendations of the Advisory Committee on Poliomyelitis Eradication, Geneva, 27-28 November 2007. Wkly Epidemiol Rec 2008, 83:25-35.
44. Posey D.L., Linkins R.W., Couto Oliveria M.J., Monteiro D., Patriarca P.A. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997, 175(Suppl. 1):S258-S263.
45. Triki H., Abdallah M.V., Ben Aissa R., Bouratbine A., Ben Ali Kacem M., Bouraoui S., et al. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 1997, 15:1123-1129.
46. Ramsay M.E., Begg N.T., Gandhi J., Brown D. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994, 13:1117-1121.
47. World Health Organization Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010, 85:213-228.